Production and Evaluation of an Avian IgY Immunotoxin against CD133+ for Treatment of Carcinogenic Stem Cells in Malignant Glioma: IgY Immunotoxin for the Treatment of Glioblastoma

Abstract EN

Background.

Glioblastoma is the most common malignant tumor of Central Nervous System.

Despite the research in therapeutics, the prognosis is dismal.

Malignant glioma stem cells (MGSCs) are a major cause of treatment failure and increasing tumor recurrence.

In general, cancer stem cells (CSCs) express prominin-1 (CD133), considered as a potential therapeutic target.

In this study, we produced an avian immunotoxin directed against the subpopulation of CD133+ CSCs within a malignant glioma.

We used the avian IgY because it has various advantages as increased affinity to mammal antigens and inexpensive obtention of large amounts of specific antibodies (approximately 1 mg/per egg).

The design, production, purification and use of IgY anti CD133 immunotoxin constitute an original goal of this research.

Methods.

The immunodominant peptide of CD133 was designed to immunize hens; also, the extracellular domain of CD133 was cloned to probe the IgY antibodies.

In parallel, a recombinant abrin A chain was produced in E.

coli in order to join it to the Fc domain of the anti-CD133 IgY to conform the immunotoxin.

This anti-CD133 IgY anti-tumor immunotoxin was tested in vitro and in vivo.

Results.

The cytotoxicity of the immunotoxin in vitro showed that IgY-abrin immunotoxin reduced 55% cell viability.

After subcutaneous MGSCs implantation, the animals treated intraperitoneally or intratumorally with the IgY-abrin immunotoxin showed more than 50% decrease of tumor volume.

Conclusion.

Results showed that the IgY-abrin immunotoxin had cytotoxic activity against CD133+ MGSCs and provides a novel approach for the immunotherapy of glioblastoma.